Forecasting Gastric Cancer Diagnosis, Prognosis, and Drug Repurposing with Novel Gene Expression Signatures

Basit Öğe Kaydı
dc.authoridDemirtas, Talip Yasir/0000-0003-0122-2767
dc.authoridGOV, ESRA/0000-0002-5256-4778
dc.contributor.authorDemirtas, Talip Yasir
dc.contributor.authorRahman, Md Rezanur
dc.contributor.authorYurtsever, Merve Capkin
dc.contributor.authorGov, Esra
dc.date.accessioned2025-01-06T17:37:32Z
dc.date.available2025-01-06T17:37:32Z
dc.date.issued2022
dc.description.abstractGastric cancer (GC) is a prevalent disease worldwide with high mortality and poor treatment success. Early diagnosis of GC and forecasting of its prognosis with the use of biomarkers are directly relevant to achieve both personalized/precision medicine and innovation in cancer therapeutics. Gene expression signatures offer one of the promising avenues of research in this regard, as well as guiding drug repurposing analyses in cancers. Using publicly accessible gene expression datasets from the Gene Expression Omnibus and The Cancer Genome Atlas (TCGA), we report here original findings on co-expressed gene modules that are differentially expressed between 133 GC samples and 46 normal tissues, and thus hold potential for novel diagnostic candidates for GC. Furthermore, we found two co-expressed gene modules were significantly associated with poor survival outcomes revealed by survival analysis of the RNA-Seq TCGA datasets. We identified STAT6 (signal transducer and activator of transcription 6) as a key regulator of the identified gene modules. Finally, potential therapeutic drugs that may target and reverse the expression of the identified altered gene modules examined for drug repurposing analyses and the unraveled compounds were further investigated in the literature by the text mining method. Accordingly, we found several repurposed drug candidates, including Trichostatin A, Vorinostat, Parthenolide, Panobinostat, Brefeldin A, Belinostat, and Danusertib. Through text mining analysis and literature search validation, Belinostat and Danusertib were suggested as possible novel drug candidates for GC treatment. These findings collectively inform multiple aspects of GC medical management, including its precision diagnosis, forecasting of possible outcomes, and drug repurposing for innovation in GC medicines in the future.
dc.description.sponsorshipHealth Institutes of Turkey (TUSEB) [2019-TA-01/3436]
dc.description.sponsorshipThis study is supported by Health Institutes of Turkey (TUSEB) in the context of the project 2019-TA-01/3436.
dc.identifier.doi10.1089/omi.2021.0195
dc.identifier.endpage74
dc.identifier.issn1536-2310
dc.identifier.issn1557-8100
dc.identifier.issue1
dc.identifier.pmid34910889
dc.identifier.scopus2-s2.0-85123569672
dc.identifier.scopusqualityQ2
dc.identifier.startpage64
dc.identifier.urihttps://doi.org/10.1089/omi.2021.0195
dc.identifier.urihttps://hdl.handle.net/20.500.14669/2263
dc.identifier.volume26
dc.identifier.wosWOS:000730487500001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofOmics-A Journal of Integrative Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241211
dc.subjectdrug repurposing
dc.subjectgastric cancer
dc.subjectgenomics
dc.subjectprognostic biomarkers
dc.subjectsystems biology
dc.titleForecasting Gastric Cancer Diagnosis, Prognosis, and Drug Repurposing with Novel Gene Expression Signatures
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu